Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2022-05-30 Investor Presentation
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF RESEARCH UPDATES ON KN046 AND KN026 AT 2022 ASCO ANNUAL MEETING
Investor Presentation Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology presenting detailed research updates on clinical trials of their drug candidates KN046 and KN026 at the 2022 ASCO Annual Meeting. It includes extensive clinical trial data, efficacy and safety results, study designs, and conclusions. The content is a presentation of research findings rather than a formal financial report, earnings release, or regulatory filing. The document is not an announcement of a report publication but contains substantive scientific and clinical data. The nature of the document aligns with an Investor Presentation (IP) as it provides detailed information on clinical progress and research updates intended for investors and stakeholders.
2022-05-30 English
CLARIFICATION ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement by Alphamab Oncology clarifying clinical data related to a previously submitted abstract for a phase II clinical trial. It discusses the withdrawal attempt of the abstract, details on patient deaths, and ongoing clinical trial status. The document is not a full clinical trial report or financial report but a clarification announcement regarding clinical data and safety information. It does not contain financial statements, management discussion, or regulatory certifications. It is also not a voting result, board change, or capital update. The document is a regulatory announcement clarifying clinical data and trial status, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories and is a general regulatory announcement related to clinical trial data clarification.
2022-05-30 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II CLINICAL TRIAL OF KN026 COMBINED WITH PALBOCICLIB AND FULVESTRANT FOR THE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HER2-POSIT
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding the dosing of the first patient in a Phase II clinical trial for a cancer drug. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or annual report content. It is a business update about clinical trial progress, which is typical for a voluntary announcement about business developments. The document is not a report or financial statement but an announcement of a clinical trial milestone. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory/business update that does not fit other specific categories.
2022-05-26 English
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Alphamab Oncology regarding the grant of award shares under a restricted share award scheme. It details the number of shares granted, the vesting schedule, and the issuance of new shares under a general mandate. The document is relatively short (3789 characters) and focuses on share awards and capital changes rather than financial results or management discussions. There is no indication that this is a full financial report, audit, or earnings release. The content fits the description of a Share Issue/Capital Change announcement, as it involves the issuance of new shares and related details. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2022-05-20 English
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 10, 2022
AGM Information Classification · 95% confidence The document is a 'Form of Proxy' for use at the Annual General Meeting (AGM) of Alphamab Oncology scheduled for June 10, 2022. It includes instructions for shareholders to appoint proxies to vote on resolutions such as receiving the audited financial statements, re-electing directors, granting mandates, and appointing auditors. The content is procedural and related to the AGM meeting arrangements rather than the actual AGM materials or presentations. It is not the Annual Report or financial statements themselves, but a proxy form for voting at the AGM. Therefore, the document fits the category of AGM Information (AGM-R), which covers materials shared during the AGM, including proxy forms.
2022-05-10 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice for the Annual General Meeting (AGM) of Alphamab Oncology, detailing the date, time, location, agenda items including resolutions to be passed, re-election of directors, and other procedural notes. It does not contain the actual financial statements or detailed reports but rather serves as an invitation and agenda for the AGM. The presence of phrases like 'NOTICE OF ANNUAL GENERAL MEETING' and detailed instructions for shareholders to attend and vote confirms this is an AGM notice document. Therefore, it fits the category of AGM Information (AGM-R). The document length and content confirm it is not a brief announcement or a report publication announcement but a full AGM notice.
2022-05-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.